The Series D round was backed by strategic investors including AstraZeneca, HAT SGR, Hitachi Ventures, and Leaps by Bayer.
"We have known Huma for several years and we’ve been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics. With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care."
— Juergen Eckhardt, EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development & Licensing
The funding round was led by Quantum Energy Partners with participation from corporate and existing investors to support global expansion.
"We have a once in a generation opportunity to build environmental and ecological restoration into the heart of the economic model. Starting with carbon, effective ecosystem markets have huge potential to accelerate the Net Zero transition and generate economic prosperity. Developing the information infrastructure that allows these markets to take off is fundamental to their growth. The raise will ensure we can continue to invest in our ratings, risk and analytics tools to make this vision a reality."
The Series C financing was led by Leaps by Bayer and Hitachi Ventures to support international expansion and platform development.
"This is a pivotal moment in Huma’s development. We have exceptional partners and strategic investors who will support us in our mission to help people worldwide live longer and fuller lives. We’re already demonstrating how ‘hospital at home’ can transform healthcare, and how decentralized clinical trials can advance research in ways that weren’t imaginable even one year ago. Now we want to accelerate the pace of change and continue to innovate for better care and research worldwide."
